Immune Thrombocytopenia ITP Market By Type (Acute Immune Thrombocytopenia, and Chronic Immune Thrombocytopenia), By Treatment (Thrombopoietin Receptor Agonist, Immunoglobulins, Corticosteroids, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others) and By Region - Trends, Analysis, And Forecast Till 2029

Report Code: PMI457820 | Publish Date: May 2024 | No. of Pages: 180

Global Immune Thrombocytopenia Itp Market Overview

Immune Thrombocytopenia Market accounted for USD 3.04 Billion in 2019 and is estimated to be USD 3.3 Billion by 2029 and is anticipated to register a CAGR of 0.30%.

Immune Thrombocytopenia ITP is a serious blood disorder that occurs due to physical injuries, infections, deficiencies, and other wounds. The adverse effects of the disease have led to a high emphasis on the research and development of newer drugs and therapeutic procedures associated with the treatment of the disease. Growing emphasis on R&D will attract huge investments and yield better products. The increasing number of product launches, coupled with advancements in betterment of existing products will have a direct impact on the growth of the market tin the coming years. Although there are very few options available for treatment of the disease, advancements in ongoing clinical trials have shown promise.

Global Immune Thrombocytopenia Itp Market Drivers & Restraints

Increasing Second- And Third-Line Therapies

The market is widely driven by increasing second- and third-line therapies. Moreover, the understanding of the disorder and therapeutic has expanded greatly, owing to the increased demand for therapy in the near future. Second-line drug therapies include high dose dexamethasone or methylprednisolone, high-dose IVIg or anti-D Ig, vinca alkaloids and danazol, the immunosuppressants cyclophosphamide, azathioprine, cyclosporine or mycophenolate mofetil, and the anti-CD-20 monoclonal antibody rituximab. For instance, in January 2020, Rigel Pharmaceuticals, Inc. announced the launch of TAVLESSE (Spleen tyrosine kinase inhibitor) in Europe with its collaborative partner Grifols S.A. The product was launched in Germany and the United Kingdom.

Rising Awareness

Advanced 3-D printing technologies which makes the manufacturing easy and less time consuming is estimated to fuel the demand of metal forming equipment in the global market in the coming future. Manufacturers are involved in improving the quality of metal forming equipment present in the market, this will enforce the consumer to replace their old metal forming equipment with the novel machines and this will accelerate the demand of metal forming equipment. Moreover, the automobile industry is continuously demanding for new and advanced metal forming equipment in the current rapid industrialization stage in the developed as well as developing economies across the globe.

Restraint:

Side Effects

The side effects associated with the available drugs for the treatment of Immune Thrombocytopenia ITP are forcing healthcare practitioners to adopt alternative treatment options such as platelet transfusion and surgery. These treatment options have higher efficacies when compared to the available drugs. This is expected to pose a challenge to the growth of the global Immune Thrombocytopenia ITP market size.

Global Immune Thrombocytopenia Itp Market Segmentations & Regional Insights

Immune Thrombocytopenia ITP market is segmented into the type, treatment and distribution channel.

Depending on the Type global Immune Thrombocytopenia ITP market is categorized into Acute Immune Thrombocytopenia ITP, and Chronic Immune Thrombocytopenia ITP. Based on the Treatment the market is divided into Thrombopoietin Receptor Agonist, Immunoglobulins, Corticosteroids, and Others. In terms of Distribution Channel, the market is divided into Hospital Pharmacy, Retail Pharmacy, and Others.

Regional insights:

Regionally, the overall industry is divided into North America, Europe, Asia Pacific, Latin America, And Middle East & Africa. North America will witness the highest growth in the coming years, driven by easier access to treatment and favorable reimbursement policies. Additionally, the presence of major market players, improving healthcare infrastructure, and growing awareness of blood disorders will have a positive influence on market growth. A substantial amount of investment has been made in developed economies such as Europe. However, emerging economies in the Asia Pacific are expected to provide a tremendous opportunity to the market. Much of the fundamental research has been conducted within the Asia-Pacific research establishments, for instance, almost first-in-class products out of all are in clinical development for the treatment of Immune Thrombocytopenia ITP. Out of which, 60% of products are being manufactured by companies in the Asia-Pacific region, including Japanese biopharma company, KM Biologics, among others. However, pipeline therapies show superior efficacy and safety profiles compared to commercially available marketed drugs. Additionally, the availability of research funding and favorable regulatory scenarios enables emerging players to enter the Immune Thrombocytopenia ITP market.

Report scope:

Attribute

Details

The base year for estimation

2019

Forecast period

2019 – 2029

Market representation

Revenue in USD Million & CAGR from 2019 – 2029

Market Segmentation

By Type - Acute Immune Thrombocytopenia ITP, and Chronic Immune Thrombocytopenia ITP

By Treatment - Thrombopoietin Receptor Agonist, Immunoglobulins, Corticosteroids, and Others

By Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and Others

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029.  For the purpose of this study, has segmented the Immune Thrombocytopenia ITP Market report based on the type, treatment and distribution channel.

Immune Thrombocytopenia ITP Market, By Type:

  • Acute Immune Thrombocytopenia
  • Chronic Immune Thrombocytopenia

Immune Thrombocytopenia ITP Market, By Treatment:

  • Thrombopoietin Receptor Agonist
  • Immunoglobulins
  • Corticosteroids
  • Others

 Immune Thrombocytopenia ITP Market, By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Immune Thrombocytopenia ITP Market, By Region:

  • North America
    • Middle East & Africa
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa
    • Latin America
        • Brazil
        • Mexico
        • Rest of Latin America
    • Asia Pacific
        • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Europe
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
      • U.S.
      • Canada

Global Immune Thrombocytopenia Itp Market Competitive Landscape & Key Players

The key players operating in the Immune Thrombocytopenia ITP market includes Amgen Inc., Novartis AG, Rigel Pharmaceuticals, Inc., Dova Pharmaceuticals, Grifols S.A, CSL Limited, Octapharma AG, Intas Pharmaceuticals Ltd., Saol Therapeutics. For instance, in 2018, Dova Pharmaceuticals announced a collaboration with Shanghai Fosun Pharmaceuticals for the development and distribution of Doptelet in China and Hong Kong. Similarly, Novartis announced the acquisition of oncology and pipeline department of Glaxo Smith Kline plc. The company plans to extend its business across the world and establish a wider customer reach.

Global Immune Thrombocytopenia Itp Market Company Profile

FAQs

Immune thrombocytopenia market accounted for US$ 3.04 billion in 2019 and is estimated to be US$ 3.3 billion by 2029 and is anticipated to register a CAGR of 0.30%.

The Immune Thrombocytopenia ITP Market is segmented into Type, Treatment, Distribution Channel and Region.

Upcoming trends in Immune Thrombocytopenia (ITP) treatment include the exploration of novel thrombopoietin receptor agonists and advancements in immune-modulating therapies, providing global opportunities for more targeted and effective interventions in ITP management.

The market is widely driven by increasing second- and third-line therapies. Moreover, the understanding of the disorder and therapeutic has expanded greatly, owing to the increased demand for therapy in the near future.

By region, the target market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. market is estimated to witness a significantly high revenue share over the forecast period.

The key players operating the target market includes, Amgen Inc., Novartis AG, Rigel Pharmaceuticals, Inc., Dova Pharmaceuticals, Grifols S.A, CSL Limited, Octapharma AG, Intas Pharmaceuticals Ltd., Saol Therapeutics.